Follow The Filings

QDEL Quidelortho Corporation

Health Care, filed as QUIDELORTHO CORP (COM), Equity Among managers we track Quote on Google Finance, opens in a new tab

No current holdings among managers we track for this security. See ownership history or the ownership grid, activity, or search.

Insider trades

Open-market buys and sales by QDEL's executives, directors and 10% owners in the last 12 months, from their Form 4s

All QDEL insider trades
  • $724K bought by 5 insiders
  • $112K sold by 1 insider outside a trading plan
  • None no planned (10b5-1) sales
  1. Joseph M. Busky CFO
    Buy
    $80K 3,370 shares at $23.66 +49% to stake
    Traded Feb 13 Filed Feb 19
  2. Brian J. Blaser CEO
    Buy
    $249K 10,540 shares at $23.59 +36% to stake
    Traded Feb 13 Filed Feb 13
  3. Matthew Strobeck Director
    Buy
    $240K 10,000 shares at $23.96 +56% to stake
    Traded Feb 13 Filed Feb 13
  4. Ann D. Rhoads Director
    Buy
    $21K 750 shares at $28.28 +5.3% to stake
    Traded Dec 10, 2025 Filed Dec 10, 2025
  5. Joseph D. Wilkins Jr. Director
    Buy
    $10K 370 shares at $27.96 +3.2% to stake
    Traded Nov 26, 2025 Filed Dec 1, 2025
  6. Joseph M. Busky CFO
    Buy
    $124K 4,770 shares at $26.06 +222% to stake
    Traded Nov 24, 2025 Filed Nov 25, 2025
  7. Kenneth J. Widder Director
    Sale
    $112K 4,026 shares at $27.81 9.8% of stake
    Traded Nov 25, 2025 Filed Nov 25, 2025
  8. Mary Lake Ph D. Polan Director
    Buy
    $22K 1,000 shares at $22.43 +8.6% to stake
    Traded Nov 21, 2025 Filed Nov 24, 2025
  9. Brian J. Blaser CEO
    Buy
    $502K 23,500 shares at $21.34 +390% to stake
    Traded Nov 19, 2025 Filed Nov 20, 2025

Also filed in the last 12 months, not counted as buying or selling: 40 stock grants, 24 share withholdings for taxes, and 5 option exercises.

SEC filings

Recent issuer filings from EDGAR, 15 shown.

Filed Form Detail Links
SCHEDULE 13G/A —
SCHEDULE 13G —
10-Q
8-K 2.02,5.02,9.01
SCHEDULE 13G/A —
8-K 1.01,9.01
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G —
10-Q
8-K 2.02,9.01
SCHEDULE 13G/A —
SCHEDULE 13G —
8-K 5.02,7.01,9.01
8-K 5.07

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $3.27B — —
Net income $0.549B -$2.05B -$1.13B
Net margin * 16.8% — —

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $1.58B $1.22B $1.45B
Total non-current assets * $7.28B $5.2B $4.32B
Total assets $8.86B $6.42B $5.77B
Total current liabilities $1.01B $0.999B $0.966B
Total non-current liabilities * $2.91B $2.44B $2.88B
Total equity $4.93B $2.98B $1.92B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $885.3M $83M $105.2M
Cash from investing -$1.64B -$0.15B -$0.193B
Cash from financing $252M $48.8M $155.8M
Net change in cash -$508.9M -$21M $71.3M

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf